GMAB
Genmab AS
NASDAQ: GMAB · HEALTHCARE · BIOTECHNOLOGY
$32.47
+0.74% today
Updated 2026-09-11
Market cap
$20.65B
P/E ratio
26.67
P/S ratio
5.07x
EPS (TTM)
$1.26
Dividend yield
—
52W range
$24 – $35
Volume
2.3M
WallStSmart proprietary scores
53
out of 100
Grade: C
Hold
Investment rating
4.0
Growth
C6.0
Quality
B8.0
Profitability
A6.0
Valuation
B2/9
Piotroski F-Score
Weak
1.7
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →251 stocks currently score above 75
Price targets
Analyst target
$38.84
+19.62%
12-Month target
$25.57
-21.25%
Intrinsic (DCF)
$58.54
Margin of safety
+48.65%
1 Strong Buy10 Buy1 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ Free cash flow $48.00M — positive
+ Revenue growth 24.90% QoQ
+ 48.65% below intrinsic value
Risks
- Piotroski 2/9 — weak financial health
- Altman Z 1.70 — distress zone
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $14.51B | $16.47B | $21.53B | $3.72B | $4.13B |
| Net income | $5.45B | $4.35B | $7.84B | $963.76M | $303.00M |
| EPS | — | — | — | — | $1.26 |
| Free cash flow | $3.60B | $7.00B | $7.58B | $1.15B | $48.00M |
| Profit margin | 37.59% | 26.42% | 36.44% | 25.89% | 19.10% |
Peer comparison
Smart narrative
Genmab AS trades at $32.47. representing a P/E of 26.67x trailing earnings. Our Smart Value Score of 53/100 indicates the stock is fair. The company scores 2/9 on the Piotroski F-Score. With an Altman Z-Score of 1.70, it sits in the distress. TTM revenue stands at $4.13B. with profit margins at 19.10%. Our DCF model estimates intrinsic value at $58.54.
Frequently asked questions
What is Genmab AS's stock price?
Genmab AS (GMAB) trades at $32.47, on a P/E of 26.7x and a P/S of 5.1x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is Genmab AS overvalued?
Genmab AS carries a Smart Value Score of 53/100 (Grade C), which we rate Hold. That score blends growth, quality, and valuation into one read. Our DCF puts intrinsic value at $58.54 versus the $32.47 price, a 48.6% margin of safety on a cash flow basis.
What is the price target of Genmab AS (GMAB)?
The 12-month analyst consensus target is $38.84, about 19.6% above the current $32.47. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
What is the intrinsic value of Genmab AS (GMAB)?
Our DCF model estimates intrinsic value at $58.54, a +48.6% margin of safety versus today's $32.47. Intrinsic value is what the projected cash flows are worth today. A positive reading means the price sits below that estimate, leaving a cushion if growth holds.
What is Genmab AS's revenue?
Genmab AS's trailing twelve-month revenue is $4.13B. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.
Altman Z-Score?
Genmab AS's Altman Z-Score is 1.70, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio5.07x
ROE13.23%
Beta0.70
50D MA$30.42
200D MA$29.34
Shares out0.61B
Float0.59B
Short ratio—
Avg volume2.3M
Performance
1 week-3.36%
1 month+1.66%
3 months+29.47%
YTD+5.42%
1 year+16.71%
3 years—
5 years—